EUVIMEDEUVIMED entdecken
Übersichtsarbeit

NSD3: A Promising Target for Cancer Therapy

Ting Huang, Bowen Zhang, Yifan Yang, Qiong Lin, Genbao Shao

Cell Biochemistry and Function · 2025

DOI: 10.1002/cbf.70071 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cell Biochemistry and Function, 2025. Verfasst von Ting Huang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Basic Medicine, School of Medicine, Jiangsu University, Zhenjiang, Jiangsu, China. Hauptthemen laut MEDLINE: Neoplasms, Histone-Lysine N-Methyltransferase, Antineoplastic Agents, Enzyme Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 89 Literaturangaben. Gefördert von: This study was supported by the Key Research and Development Program of Jiangsu Province (grant no. BE2020678)..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Over the past 24 years, nuclear receptor‐binding SET domain protein 3 (NSD3) has emerged as a critical regulator of cellular physiological processes. As a histone methyltransferase targeting H3K36, NSD3 catalyzes the addition of methyl groups to histone residues, a process that profoundly influences genome imprinting, gene transcription, and genome stability, thereby modulating gene expression. Amplification, mutations, and fusion events involving the NSD3 gene have been strongly linked to the pathogenesis of various cancers, highlighting its role as a key regulator of tumorigenesis. This review provides an overview of the general structure and biological functions of NSD3, followed by an analysis of NSD3's role in relation to the hallmarks of cancer as described by Hanahan and Weinberg. Targeting NSD3 has become a major focus of research, with significant efforts directed toward the development and clinical application of NSD3 inhibitors. However, challenges related to specificity and selectivity have hindered progress in this area. Despite these obstacles, the successful development and clinical advancement of other histone methyltransferase inhibitors have provided encouragement to researchers, driving the active pursuit of NSD3‐targeted therapies for cancer treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsHistone-Lysine N-MethyltransferaseAntineoplastic AgentsEnzyme InhibitorsNuclear ProteinsHumansMolecular Targeted TherapyAnimals

Stichwörter der Autor:innen

NSD3cancermethylationmethyltransferasesignaling pathwaytherapeutic target

Substanzen

Histone-Lysine N-MethyltransferaseNSD3 protein, humanAntineoplastic AgentsEnzyme InhibitorsNuclear Proteins

Autor:innen und Institutionen

  • Department of Basic Medicine, School of Medicine, Jiangsu University, Zhenjiang, Jiangsu, China.
  • Institute of Urinary System Diseases, The Affiliated People's Hospital, Jiangsu University, Zhenjiang, China.

Förderung

  • This study was supported by the Key Research and Development Program of Jiangsu Province (grant no. BE2020678).

Zitieren

APA

Huang, T., Zhang, B., Yang, Y., Lin, Q., & Shao, G. (2025). NSD3: A Promising Target for Cancer Therapy. Cell Biochemistry and Function. https://doi.org/10.1002/cbf.70071

Vancouver

Huang T, Zhang B, Yang Y, Lin Q, Shao G. NSD3: A Promising Target for Cancer Therapy. Cell Biochemistry and Function. 2025. doi:10.1002/cbf.70071

BibTeX
@article{Huang2025,
  author = {Huang, Ting and Zhang, Bowen and Yang, Yifan and Lin, Qiong and Shao, Genbao},
  title = {NSD3: A Promising Target for Cancer Therapy},
  journal = {Cell Biochemistry and Function},
  year = {2025},
  doi = {10.1002/cbf.70071}
}
Kostenlos starten →